



February 28, 2017

SUMMARY OF ORIGINAL BILL: Requires the Commissioner of the Department of Mental Health and Substance Abuse Services (DMHSAS), in collaboration with the Commissioner of the Department of Health (DOH), to develop recommended nonresidential treatment guidelines for the use of buprenorphine that can be used by prescribers in this state as a guide for caring for patients by January 1, 2018. Requires the Commissioner to review the nonresidential buprenorphine treatment guidelines by September 30 of each year beginning in 2019, and to post them on the DMHSAS and the DOH websites. Requires the Commissioner of DMHSAS to submit the treatment guidelines to each health-related board that licenses any practitioner authorized by the state to prescribe buprenorphine-containing products for the treatment of an opioid use disorder. Requires the health-related boards to review the guidelines, determine how they should be used by the licensees, and notify all of its licensees through routine bulletins or newsletters of the existence of the nonresidential buprenorphine guidelines and standards.

FISCAL IMPACT OF ORIGINAL BILL:

NOT SIGNIFICANT

SUMMARY OF AMENDMENT (004287): Deletes the provision of the bill that requires the health-related boards to notify all licensees through routine bulletins or newsletters of the existence of the nonresidential buprenorphine guidelines and standards and replaces it with language that allows the boards to post the guidelines and standards on the licensing board's website.

FISCAL IMPACT OF BILL WITH PROPOSED AMENDMENT:

Unchanged from the original fiscal note.

Assumptions for the bill as amended:

- Based on information provided by DMHSAS, any fiscal impact associated with developing, reviewing, and posting guidelines will be minimal and can be absorbed within existing resources without an increased appropriation or reduced reversion.
- Based on information provided by the DOH, health-related boards can review the guidelines during normal operations at regularly-scheduled board meetings and post the

guidelines on the licensing board's websites within existing resources; therefore, any fiscal impact on health-related boards is estimated to be not significant.

CERTIFICATION:

The information contained herein is true and correct to the best of my knowledge.

A handwritten signature in blue ink that reads "Krista M. Lee". The signature is written in a cursive, flowing style.

Krista M. Lee, Executive Director

/jem